Next 10 |
home / stock / cdtx / cdtx articles
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak&...
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigat...
Shares of Teradyne, Inc. (NASDAQ:TER) rose sharply in today's pre-market trading after the company posted upbeat first-quarter results and iss...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical develo...
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financia...
Shares of Hibbett, Inc. (NASDAQ:HIBB) rose sharply in today's pre-market trading after the company agreed to be acquired by JD Sports Fashion ...
Cidara Therapeutics Inc (NASDAQ:CDTX) shares are trading lower by 24.4% to $0.52 Monday afternoon. The company announced a 1-for-20 reverse stock s...
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonst...
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara's Cloudbreak platform for the devel...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / May 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cidara Therapeutics, Inc. ("Cidara" or "the Company") (NASDAQ:CDTX). Investors who purchased Cidara securities are encouraged to obtain additional informa...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak&...
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serio...